Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | BLM | P54132 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.35 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.32 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.32 |
| ▸ | GABRP | O00591 | 1/20 | 0.32 |
| ▸ | GABRD | O14764 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2654446 | 0.98 | LMNA (0.41) | LMNACYP1A2TSHRSMN1; SMN2BLM | |
| Water SCHEMBL2651084 | 0.98 | LMNA (0.41) | LMNACYP1A2TSHRSMN1; SMN2BLM | |
| SCHEMBL13512958 | 0.98 | LMNA (0.39) | LMNACYP1A2TSHRSMN1; SMN2BLM | |
| SCHEMBL18281682 | 0.88 | — | — | |
| SCHEMBL21696279 | 0.87 | LMNA (0.40) | LMNACYP1A2TSHRSMN1; SMN2BLM | |
| SCHEMBL26547484 | 0.83 | LMNA (0.46) | LMNACYP1A2TSHRBLMALDH1A1 | |
| Hydrochloric Acid SCHEMBL15775036 | 0.80 | L3MBTL1 (0.38) | LMNACYP1A2TSHRSMN1; SMN2BLM | |
| SCHEMBL8430963 | 0.78 | LMNA (0.46) | LMNACYP1A2TSHRBLMALDH1A1 | |
| Succinic Acid SCHEMBL2447721 | 0.76 | LMNA (0.45) | LMNACYP1A2TSHRSMN1; SMN2BLM | |
| SCHEMBL498155 | 0.76 | TSHR (0.56) | LMNACYP1A2TSHRSMN1; SMN2BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1390521-B1 | GLYCOPEPTIDE ANTIBIOTICS | WYETH CORP (US) | 2010-08-18 | — | — | EP | claimed |
| EP-1390521-A4 | GLYCOPEPTIDE ANTIBIOTICS | WYETH CORP (US) | 2006-11-15 | — | — | EP | claimed |
| US-6964860-B2 | Glycopeptide antibiotics | WYETH HOLDINGS CORPORATION (US) | 2005-11-15 | — | — | US | claimed |
| EP-1390521-A1 | GLYCOPEPTIDE ANTIBIOTICS | Wyeth Holdings Corporation (US) | 2004-02-25 | — | — | EP | claimed |
| US-20030092610-A1 | Glycopeptide antibiotics | AMERICAN CYANAMID COMPANY | 2003-05-15 | — | — | US | claimed |
| WO-2002086141-A1 | GLYCOPEPTIDE ANTIBIOTICS | WYETH HOLDINGS CORPORATION (US) | 2002-10-31 | — | — | WO | claimed |
| US-12493019-B2 | Methods of determining protein stability | AMGEN INC. (US) | 2025-12-09 | — | — | US | disclosed |
| US-20250066470-A1 | TIGIT AND CD112R BLOCKADE | AMGEN INC. (US) | 2025-02-27 | — | — | US | disclosed |
| US-12078701-B2 | Methods of fingerprinting therapeutic proteins via a two-dimensional (2D) nuclear magnetic resonance technique at natural abundance for formulated biopharmaceutical products | AMGEN INC. (US) | 2024-09-03 | — | — | US | disclosed |
| US-11919953-B2 | TIGIT and CD112R blockade | AMGEN INC. (US) | 2024-03-05 | — | — | US | disclosed |
| US-20240034753-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. | 2024-02-01 | — | — | US | disclosed |
| EP-4029877-B1 | INTERLEUKIN-21 MUTEINS AND METHODS OF TREATMENT | AMGEN INC (US) | 2024-01-17 | — | — | EP | disclosed |
| US-20230381276-A1 | INTERLEUKIN-21 MUTEIN/ ANTI-PD-1 ANTIBODY CONJUGATES | AMGEN INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-5061808-A | 2-oxo-1-pyrrolidine carboxylic acid esters | WARNER-LAMBERT COMPANY (US) | 1991-10-29 | — | — | US | disclosed |
| WO-1990002112-A1 | SUBSTITUTED ARYL UREAS AS HIGH POTENCY SWEETENERS | THE NUTRASWEET COMPANY (US) | 1990-03-08 | — | — | WO | disclosed |
| EP-0355819-A1 | Substituted aryl ureas as high potency sweeteners | THE NUTRASWEET COMPANY (a Delaware corporation) (US) | 1990-02-28 | — | — | EP | disclosed |
| EP-0224751-B1 | DIPHOSPHONIC-ACID DERIVATIVES, PROCESS FOR PREPARING THEM AND MEDICINES CONTAINING THESE COMPOUNDS | Roche Diagnostics GmbH (DE) | 1990-01-24 | — | — | EP | disclosed |
| US-4876343-A | Process for statine and statine analogs | WARNER-LAMBERT COMPANY (US) | 1989-10-24 | — | — | US | disclosed |
| US-4719203-A | CALCIUM METABOLISM DISORDERS | BOEHRINGER MANNHEIM GMBH (DE) | 1988-01-12 | — | — | US | disclosed |
| EP-0224751-A1 | Diphosphonic-acid derivatives, process for preparing them and medicines containing these compounds | Roche Diagnostics GmbH (DE) | 1987-06-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092610-A1 | Glycopeptide antibiotics | ST6GAL1, FUT6, GALNT6 | LMNA 4746/4885CYP1A2 3127/4885TSHR 719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.